Cerulean Pharma
Cambridge
About Cerulean Pharma
Cerulean Pharma Inc. is a privately-held biopharmaceutical company focused on the development of novel nanotechnology-based therapeutics in the areas of oncology, cardiovascular, autoimmune and inflammatory diseases. The Company has assembled a world-class management team, board of directors and scientific advisory board that collectively have a significant track record of business building, product development and scientific breakthroughs from companies and institutions such as Cubist, GlaxoSmithKline, Merck, Millennium Pharmaceuticals, Inc., Pfizer, Wyeth, the Massachusetts Institute of Technology, Harvard Medical School, MD Anderson, Fox Chase Cancer Center and the Arizona Health Center.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $152.7M
- Funding stage: M&A
- Last round: Post-IPO Equity (Apr 2015)
- Ticker: nasdaq:CERU
- Website: darebioscience.com
- Phone: (617)494-1544
Industries & Categories
Biotechnology, Health Care, Nanotechnology, Oncology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/cerulean-pharma-3514672 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.